Abstract: Corn rootworm infestations can be controlled by inoculating the soil with parasporal-inclusion forming species of Bacillus laterosporus to produce viable populations of that bacteria effective to reduce crop damage. Viable populations of B. laterosporus can be initiated by application to the soil, of effective amounts of vegetative cells or spores of the organism either in liquid suspensions, or as coatings on seeds or granular substrates.

Abstract: The present invention provides a pharmaceutical product for combating cancer with vincristine as active constituent, the neuropathic complications being prevented by a peptide. The product according to the invention contains:(a) vincristine or a salt thereof, and(b) a peptide having the general formula I:H--L--Met(X)--L--Glu--L--His--L--Phe--A--B--Yor a salt or an N-acyl derivative thereof in which Met(X) represents the amino acid radical Met, Met(O) or Met(O.sub.2),A represents the amino acid radical L-Lys, D-Lys, L-Arg or D-Arg,B represents the amino acid radical L-Trp or L-Phe,Y represents the hydroxyl group, an esterified hydroxyl group or an optionally substituted amino group.

Abstract: A powdery complex is obtained by combining a useful substance such as vitamin E and liquid fatty oil with albumin. This powdery complex has excellent storage stability and can keep the useful substance contained therein stably for a long time.

Abstract: Methods of treating diseases in swine are disclosed using porcine interferon alpha and/or gamma.

Abstract: A stable reference solution for calibrating and monitoring blood gas instrumentation is disclosed. The solution comprises an aqueous mixture containing a hemoglobin solution derived from a mammalian source which comprises at least about 95% reduced hemoglobin. The solution additionally contains a bicarbonate buffer and a metal catalyzed methemoglobin reducing system and an organic buffer. To provide a control element having a variety of properties similar to fresh, whole, human blood, the reference solution is stored in a sealed ampule under an inert atmosphere containing CO.sub.2 until just prior to use. The ampule is subsequently opened and the solution is equilibrated with a gas mixture having components which provide gasses in a physiological range to the solution. The solution is characterized by exhibiting properties similar to fresh blood subsequent to equilibration and an extended storage life prior to equilibration.

Abstract: Growth hormone is conjugated to any ligand, preferably a protein such as bovine serum albumin, optionally by use of a cross-linking agent such as a carbodiimide. The conjugates have enhanced activity when compared with unmodified growth hormone, and also better aqueous solubility at acid pH's.

Abstract: The invention relates to a process for manufacturing organized collagen structures, particularly of human origin and the organized collagen structures corresponding thereto. These organized structures may be either fibres or membranes. According to the process, a specimen of animal or human tissue is ground in a saline solution after washing and aseptization, in order to solubilize the collagen contained in said specimen. There is then added to the extract thus obtained, which is composed of a minimum quantity of collagen fibrils and which is free of non-fibrillary collagen precipitate, a catalyst promoting the reconstitution of collagen fibres. Following a maturation process, the reconstituted organized structures are separated from the aqueous medium by centrifuging, and are then washed, aseptized, conditioned, lyophilized and sterilized.

Abstract: A method of treating birds by administering birds in ovo a T-cell growth factor comprising avian IL-2 is disclosed. The method is preferably carried out on chickens with 30K chicken IL-2 on about the eighteenth day of incubation. The method may be employed to increase the weight of treated birds after hatch. A vaccine may optionally be administered concurrently with the avian IL-2.

Abstract: Low doses of interferon contacted with the oral and pharyngeal mucosa of a patient in conjunction with administration of radiation therapy or chemotherapy reduces the toxic side effects associated with administration of said cancer therapy.

Abstract: Viscoelastic solution including a buffered solution, 0.01-8% chondroitin sulfate, 0.1-8% hydroxypropyl methylcellulose, pH adjusted to 6.0-8.0 at a osmolality between 200-400 mOsmol/L. The buffered solution can be HEPES buffered minimum essential media (MEM), phosphate buffer saline (PBS), buffered balanced salt solution, or TC199. A cell growth factor or cell growth supplement is included in the solution.

Abstract: Nuclear polyhedrosis viruses, for example, Autographa californica nuclear polyhedrosis virus (AcMNPV), useful in the control of lepidopterous larvae such as the larvae of the cabbage looper Trichoplusia ni, have been found to have enhanced infectivity when mixed with certain proteins obtained from the granulin fraction of Trichoplusia ni granulosis virus (TnGV) or Heliothis armigera granulosis virus (HaGV), and from the polyhedrin fraction of AcMNPV viruses. The proteins from the TnGV granulin fraction have molecular weights of about 101 and about 104 Kd. The enhanced infectivity is correlated to biochemical and structural changes in the T.ni peritrophic membrane.

Abstract: The invention discloses a novel use of Mullerian Inhibiting Substance (MIS) as a contraceptive agent. MIS has been found to reversably inhibit the maturation of oocytes in vitro. Additionally, the invention provides a means for restoring the fertility of females who are infertile due to abnormal production of MIS.

Abstract: The invention is concerned with a process for producing an .alpha.-lactalbumin-enhanced fraction from a liquid containing whey protein including .alpha.-lactalbumin and .beta.-lactoglobulin which comprises subjecting said liquid to ultrafiltration using a membrane having a molecular weight cut off of essentially 100,000 to form a permeate having a protein content in which the proportion of .alpha.-lactalbumin is enhanced relative to the proportion obtaining in the protein content of said liquid.

Abstract: Continuous hydrolyzing of keratinaceous material is effected in an elongated hydrolyzing vessel (1) under suitable pressure and temperature which is established by direct steam injection through injection valves, whereby the product mass is heated, fluidized and agitated at one and the same time.An inlet chute (2), which is closed in a pressure-proof manner, leads the material in batches and at intervals into the vessel (1), and an outlet chute (3) at intervals leads the hydrolyzed material to an economizer (4) and further to a pressure-free removal vessel (10).The product mass in the hydrolyzing vessel (1) moves through the vessel as plunger flow established by the overpressure in the inlet chute (2).

Abstract: Purified Gal/GalNAc adherence lectin of Entamoeba histolytica is used for development of a vaccine to prevent human amebiasis.

Abstract: The rate of trancytosis of antibodies across the blood-brain barrier is increased by cationizing the antibodies to provide cationized antibodies having an isoelectric point of between about 8.0 to 11.0. The increased rates of transport across the blood-brain barrier makes such cationized antibodies useful for both neurodiagnostic and neuropharmaceutical purposes. Methods for preparing such cationized antibodies are disclosed.

Abstract: A method is provided for inhibiting the .gamma.-globin to .beta.-globin switching in subjects afflicted with .beta.-globin disorders. The method is particularly adapted for ameliorating the clinical symptoms of sickle cell disease or .beta.-thalassemias by periodically introducing into the subject prio r to natural completion of the switching process activin, inhibin, an inhibin chain or mixtures thereof.

Abstract: Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG).

Abstract: Lymphocytosis promoting factor (LPF) and filamentous hemaglutinin (FHA) are isolated from the growth medium of the Bordatella pertussis organism and purified by selecting adsorbing the LPF and FHA on a selective adsorbing medium, such as filter aids or gel filtration media, at low ionic strength and subsequently removing the adsorbed LPF and FHA at using an aqueous medium of high ionic strength, either simultaneously or sequentially. Prior to desorbtion of the LPF and FHA, the adsorbing medium may be contacted with an aqueous solution of a non-ionic detergent, which enables the LPF and FHA subsequently desorbed to be substantially free from contamination by lipopolysaccharides (LPS). The LPF and FHA may be further purified on hydroxyapatite. The LPF and FHA may be detoxified separately or together by contacting with a cross-linking agent, such as glutaraldehyde or formaldehyde, in the presence of an anti-aggregation agent.

Abstract: Method of preventing or treating a Pseudomonas aeruginosa infection. Method comprises topical application of antibodies to P. aeruginos under conditions and in an amount sufficient to prevent or treat the infection in a mammal. In one embodiment, the antibodies are administrered in form of an aerosol. A preferred dosage for polyclonal antibody preparations (i.e. ISG or high titer P. aeruginosa ISG) ranges from 2 mg/kg to 100 mg/kg body weight of the mammal. A preferred monoclonal antibody dosage ranges from 0.02 to 1.0 mg/kg of body weight.